Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Tobacco Dependence
Interventions: varenicline, placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, PreDiabetes
Interventions: Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39); Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more

Conditions: Andersen-Tawil Syndrome
Interventions: Potassium, Acetazolamide; Dietary Supplement · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 10 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Primary Immune Thrombocytopenia
Interventions: Ianalumab, Eltrombopag, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more

Conditions: NMO Spectrum Disorder, Spasticity, Muscle
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Michael, Levy M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke
Interventions: Telerehabilitation, Sinemet Pill, Placebo; Device · Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Ischemic Stroke, Ischemic Stroke
Interventions: Tirofiban Hydrochloride, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cannabis, Pain, Tolerance, Hyperalgesia
Interventions: Active Cannabis, Placebo Cannabis; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Postoperative
Interventions: Gabapentin, Placebo; Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Brow Ptosis, Facial Scarring
Interventions: 5-Fluorouracil, Normal Saline Flush, 0.9% Injectable Solution; Drug
Lead sponsor: Eyelid and Facial Consultants; Other
Eligibility: 40 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Houma, Louisiana • New Orleans, Louisiana

Conditions: Hypogonadism, Opioid-Related Disorders, Male Infertility
Interventions: Clomiphene citrate, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus Type 2
Interventions: Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 64
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more

Conditions: Community-acquired Pneumonia, Bacterial Pneumonia
Interventions: CMTX-101, Placebo; Drug
Lead sponsor: Clarametyx Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more

Conditions: Metastatic Breast Cancer
Interventions: Bevacizumab [Avastin], Paclitaxel, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 66
States / cities: Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more

Conditions: Healthy
Interventions: Instrument Assisted Soft Tissue Mobilization, Walking Treatment; Other
Lead sponsor: Beth Marschner; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Minot, North Dakota

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: COVID-19
Interventions: Lenzilumab, Placebo, Remdesivir; Biological · Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more

Conditions: Schizophrenia
Interventions: Minocycline, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Schizophrenia, Schizophreniform Disorder
Interventions: Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI); Drug · Behavioral · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 40 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: mifepristone, placebo, nab-paclitaxel; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Weight Loss
Interventions: Dapagliflozin, Placebo, Weight maintenance, Ad libitum dietary intake, Dietary restriction; Drug · Behavioral
Lead sponsor: Christopher Bell; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Fort Collins, Colorado

Search by objective public record fields.

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Metformin Treatment in Progressive Multiple Sclerosis

Cardiovascular Effects of GLP-1 Receptor Activation

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

Repeated Cannabis Administration on Experimental Pain and Abuse Liability

Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children

The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair

Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Effects of Instrument Assisted Soft Tissue Mobilization on Healthy Tissue Regarding Range of Motion and Gait

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

DECIFER: Depression and Citalopram In First Episode Recovery

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?